Form 4: Edgewise Therapeutics Executive Alan J. Russell Reports Stock Transactions

Alan J. Russell, Chief Scientific Officer of Edgewise Therapeutics, reports the acquisition and disposal of company stock and restricted stock units to cover tax obligations.

Summary

• On May 1, 2025, Alan J. Russell, the Chief Scientific Officer of Edgewise Therapeutics, acquired 5,209 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• Also on May 1, 2025, 5,209 Restricted Stock Units converted to common stock.
• On May 2, 2025, Russell sold 1,551 shares of common stock at an average price of $16.4542 per share.
• The sale was to cover statutory tax withholding obligations related to the vesting of the RSUs.
• Following these transactions, Russell directly owns 18,521 shares of Edgewise Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing primarily reports routine stock transactions related to executive compensation and tax obligations.

Positives

• The vesting of RSUs indicates a form of compensation and alignment of the executive's interests with the company's performance.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking to understand management's perspective on the company's stock.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The 'sell-to-cover' practice for tax obligations is a common strategy among executives receiving equity compensation.
• Comparable companies in the biotechnology sector, such as BioMarin Pharmaceutical and Sarepta Therapeutics, also see regular Form 4 filings from their executives.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
• Transparency through Form 4 filings helps maintain investor confidence.

Key Dates

Keywords

EWTX, Edgewise Therapeutics, Russell Alan J, Form 4, Stock Sale, Restricted Stock Units, Insider Trading